Protein Signals - Week of August 17, 2026

Deep Dive - Ranchbot Raises $15 Million Series B and Moves Global HQ to Fort Worth

Ranchbot, the Australian remote-ranch monitoring company founded in 2014 as Farmbot, closed more than US$15 million (A$22 million) led by Lewis & Clark Partners with Fulcrum, Builders VC, Cultiv8, Lever VC, and Macdoch, and flipped into a Delaware parent headquartered in Fort Worth. Company materials claim more than 12,000 customers managing roughly 10 million cattle and 15 million sheep, with IoT plus satellite connectivity aimed at tanks, troughs, pumps, and other fixed assets rather than animal wearables. Watch whether U.S. logos attach beyond water and whether named integrations with wearable or distributor partners prove the infrastructure-layer thesis over the next 12 to 24 months.

Merck Animal Health received USDA approval for INNOVAX ND-IBD-ILT, which company materials call the first recombinant vaccine covering Newcastle, infectious bursal disease, infectious laryngotracheitis, and Marek’s disease in a single hatchery dose, with U.S. commercial availability slated for the fourth quarter of 2026. The product targets labor and program complexity at the hatchery, where competitors such as Zoetis and Boehringer sell multi-product vaccination stacks rather than one combined recombinant shot. Watch Q4 2026 hatchery uptake and whether integrators retire farm-side boosters enough to shift share in U.S. broiler and layer vaccination budgets.

Lactalis is buying Saputo’s United Kingdom operations, including five facilities and brands such as Cathedral City and Wensleydale, for £988 million against a portfolio Saputo said generated about £1.2 billion in trailing revenue and roughly 7% of group sales. The deal extends Lactalis’s recent UK nutrition push after the £55 million Protein Works purchase and tightens branded dairy consolidation versus peers such as Danone in functional nutrition. Watch whether Saputo redeploys proceeds into higher-return North American or specialty protein capacity, and whether remaining UK mid-tier cheese brands seek partners under Lactalis-scale private-label and retail pressure.

JBS reported about $23.9 billion in second-quarter revenue while naming Wesley Batista Filho global CEO from January 2027 and expanding credit capacity toward $4.2 billion as North American beef margins stayed under pressure. Adjusted profitability compressed even as top-line grew, a pattern echoed by Tyson’s concurrent beef weakness rather than a single-company accident tied only to JBS plants. Watch the 2027 leadership handoff against cattle-supply recovery and whether further plant rationalization arrives before leverage metrics normalize toward historical mid-cycle levels.

InnovAsian Cuisine Enterprises, Nichirei Foods’ North American subsidiary, is building a roughly 180,000-square-foot chicken processing plant in Jonesboro with a $150 million investment and about 200 jobs, targeting production by spring 2028. The facility aims at frozen prepared foods where Nichirei competes with Conagra and Kraft Heinz more than with primary processors such as Tyson or Pilgrim’s Pride. Watch whether Japanese capital keeps adding U.S. further-processing capacity if domestic labor costs and HPAI-driven poultry volatility stay elevated through 2027.

Nbryo, a Brisbane cattle-breeding technology company commercialising embryo multiplication for beef and dairy herds, received A$2 million from Queensland’s Sowing the Seeds of Farming Innovation Fund on August 12, the fund’s first disclosed cheque and a step that takes its seed capital to about A$20 million. The state equity sits beside specialist livestock tech financing such as Ranchbot’s Series B rather than crop-sensor rounds, and targets cheaper access to superior genetics versus conventional multi-year breeding cycles. Watch whether Nbryo converts the capital into commercial producer contracts in Queensland’s beef herd and whether export genetics customers follow within 18 months.